Forensic · KPHMW
KIORA PHARMACEUTICALS INC
Top signals
Shelf Filed Recent
S-3 shelf registration filed in the last 6 months (dilution capacity).
+6
Bear case preview · free
Kiora Pharmaceuticals presents a limited near-term risk profile based on algorithmic screening, with the primary concern being a recently filed S-3 shelf registration that creates meaningful dilution capacity for equity issuance. This shelf registration, filed within the past six months, suggests the company may access capital markets opportunistically, which could materially increase share count and pressure existing shareholders if drawn upon. Monitor quarterly filing cadence and any prospectus supplements over the next 60-90 days to assess whether the company begins utilizing this shelf capacity and at what pace capital raises might occur.
↑ That's free. The $9 report goes deeper: every filing cited by accession number, 36-month chronology, what to watch next.
What we checked
✓ Red flags · 36mo
0 8-K events (bankruptcy, delisting, restatement, auditor, officer)
✓ Cyber · 12mo
0 Item 1.05 disclosures + buried-cyber scan
✓ Dilution · 24mo
1 S-3 + 424B5 filing
✓ Buried events
Item 8.01 sections classified for hidden material disclosures
$9
· one-time · emailed in under a minute
The full bear case on KPHMW
Plain-English brief. Every signal cited to the exact SEC filing. 36-month chronology. What changes next.
✓ No-signals refund: if the algorithm finds zero red flags on your ticker, reply "refund" and I send the $9 back same day. No questions.
Not ready to buy? Get a free preview by email instead
We'll email you the top 3 signals on KPHMW + a discount code for the full report. No subscription, no spam.
Score another ticker
Not investment advice. Every signal grounded in a specific SEC filing. Companies may respond via info@filingfirehose.com.